Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2019

View Archived Issues

Fate Therapeutics gives update on phase I study of FT-500

Amgen identifies KRAS mutant inhibitors

Entasis Therapeutics initiates global phase III ATTACK study of ETX-2514SUL

First subject dosed in phase I study of SM-07883

FDA clears IND application for phase I/II study of HMI-102 gene therapy candidate

Patient recruitment ongoing in phase I study of TPST-1120

Preclinical results for anti-HER2 TLR8 agonist conjugate for the treatment of HER2-expressing tumors

Antigen transfer can induce CAR T friendly fire

Promising preclinical data presented for the anti-CD39 antibody TTX-030

Bayer reports phase I results for BAY-1125976

Mkrn3 gene overexpression in mice generates model of delayed puberty

K-975 shows strong antitumor effect in preclinical models of malignant pleural mesothelioma

Chung-Ang University patents new compounds for cartilage regeneration

Acceleron discontinues development of systemic muscle agent ACE-2494

Merck & Co. presents new antibacterials

Multi-peptide Top2A vaccine for immunoprevention of triple-negative breast cancer

5MP1 role in pancreatic cancer progression: potential prognostic biomarker and therapeutic target

Genentech and Roche identify anti-Gram-negative bacterial compounds

Anti-BSP fused to CPPs shows antimetastatic potential in preclinical breast cancer models

Metformin has beneficial effects in Alzheimer's disease model

Small-molecule PD-L1 inhibitor MAX-10181 shows similar antitumor efficacy to durvalumab in mice

SIMM describes bile acid receptor antagonists

New phase I trial explores use of UB-221 for chronic spontaneous urticaria

Phase I microdose study of radiolabeled PL-8177 meets primary and secondary endpoints

Merrimack discontinues development of MM-310 owing to cumulative peripheral neuropathy in phase I

FDA approves Ibrance to treat men with HR-positive, HER-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...